Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy wins WHO approval for three HIV drugs

Ranbaxy says that the World Health Organisation has included the company's three HIV treatments in its pre-qualification list

India-based Ranbaxy has revealed that the World Health Organisation (WHO) has included the company's three HIV treatments in its pre-qualification list.

Ranbaxy says it now has 15 Anti Retroviral products (ARVs) in WHO's pre-qualification list, consisting of single and fixed dose combination products. The products are manufactured at the company's accredited sites in India.

The newly included ARVs are presented in compliance kit packs and are designed to enhance patient compliance for medication and are the latest additions to the WHO list.

The compliance packs contain two fixed dose combination tablets of lamivudine or zidovudine or Stavudine, with a single tablet of efavirenz. Of these, lamivudine or stavudine and efavirenz formulations are the first by any company on the WHO list, said Ranbaxy.

Ranbaxy has already filed a range of ARVs for FDA approval and has begun receiving tentative approvals from the US Federal agency under the President's Emergency Plan For AIDS Relief (PEPFAR) programme.

On 10 September, Ranbaxy's shares traded 1.3 per cent up at INR 415.30 on the Mumbai Stock Exchange.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics